Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

NCT ID: NCT05886218

Last Updated: 2025-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

215 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-08

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sugammadex

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quantitative Neuromuscular Function Monitoring

Quantitative electromyographic (EMG) monitoring

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age greater than 18 years
* scheduled for an elective laparoscopic gastric bypass procedure

Exclusion Criteria

* age less than 18 years
* pregnancy
* prisoners
* significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
* patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\>98%)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Davis

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UC Davis Medical Center

Sacramento, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ana P Arias, BS

Role: CONTACT

916-703-5456

Julio J Arana Pineda, BA

Role: CONTACT

916-734-4074

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ana Arias

Role: primary

916-703-5456

Neal Fleming, MD, PhD

Role: backup

916 734-5046

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2004503

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.